Marksans Pharma Shares Jump 15% After Q4 Profit Rises 64% YoY; Recommends 90% Final Dividend 

Synopsis: Marksans Pharma Ltd reported a strong Q4 FY26 performance with healthy growth in revenue and profitability, supported by steady demand across key export markets and improved operational performance. The company also announced a final dividend of Rs. 0.90 per equity share for FY26. 

Marksans Pharma Ltd is a pharmaceutical company engaged in the manufacturing and marketing of generic formulations across therapeutic segments. The company has a strong presence in regulated international markets including the US, UK, and Australia, with a diversified product portfolio spanning over-the-counter and prescription medicines. 

Marksans Pharma currently has a market capitalization of Rs. 11,388 crore, while the stock trades around Rs. 248 up by 13% compared to its previous close of Rs. 220. The company trades at a P/E ratio of 31.6 and has reported healthy return ratios with ROCE of 20% and ROE of 16.8%. The book value of the company stands at Rs. 59.3 per share. 

Marksans Pharma reported revenue from operations of Rs. 856.11 crore in Q4 FY26 compared to Rs. 754.43 crore in Q3 FY26, registering a sequential growth of around 13%. On a year-on-year basis, revenue increased by nearly 21% compared to Rs. 708.46 crore reported in Q4 FY25. 

Total expenses stood at Rs. 691.29 crore during Q4 FY26 compared to Rs. 623.95 crore in Q3 FY26, reflecting an increase of around 11% sequentially due to higher business activity and operational expansion. Compared to Rs. 607.70 crore reported in Q4 FY25, expenses increased by around 14% year-on-year. 

Profit before tax came in at Rs. 199.99 crore in Q4 FY26 compared to Rs. 150.62 crore in Q3 FY26, registering a strong sequential growth of around 33%. On a year-on-year basis, PBT increased by approximately 72% compared to Rs. 116.09 crore reported in Q4 FY25. 

Profit after tax stood at Rs. 149 crore during Q4 FY26 against Rs. 113.69 crore in Q3 FY26, reflecting a QoQ growth of around 31%. Compared to Rs. 90.58 crore reported in Q4 FY25, net profit surged by nearly 59% year-on-year. 

The Board of Directors recommended a final dividend of Rs. 0.90 per equity share of face value Re. 1 each for FY26, representing a 90% payout. The proposed dividend is subject to shareholder approval at the upcoming Annual General Meeting (AGM) and will be credited or dispatched within 30 days from the date of the AGM. 

Industry Outlook 

India’s pharmaceutical sector continues to witness strong growth driven by rising healthcare demand, export opportunities, and government support for domestic manufacturing. India remains one of the world’s largest suppliers of generic medicines and vaccines, exporting pharmaceutical products to more than 150 countries. 

Government initiatives such as the Production Linked Incentive (PLI) scheme, API manufacturing support, and increased healthcare spending are expected to strengthen the sector further. The Indian pharmaceutical market is projected to grow significantly over the coming years, supported by rising chronic disease treatment demand, expanding healthcare access, and growing exports from regulated markets. 

Marksans Pharma delivered a strong Q4 FY26 performance with healthy growth in revenue, profitability, and earnings. The company reported robust year-on-year improvement in net profit and maintained steady operational momentum across key global markets. The announcement of a 90% final dividend further reflects management confidence and healthy cash generation. 

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.

The post Marksans Pharma Shares Jump 15% After Q4 Profit Rises 64% YoY; Recommends 90% Final Dividend  appeared first on Trade Brains.